•  
  •  
 

Acta Universitatis Lodziensis, Folia Biologica et Oecologica

Abstract

Seven-transmembrane (7TM) receptors are one of the most important proteins involved in perception of extracellular stimuli and regulation of variety of intracellular signaling pathways. Divergence of receptor types, their ligands and signaling pathways makes 7TM receptors important factors in pathology of many diseases. This review focused on the main diseases in which involvement of 7TM receptors was established e.g., retinitis pigmentosa, severe obesity, and dwarfism. Recent findings of aberrant expression of 7TM receptors in development of cancer were also summarized.

Keywords

Seven-transmembrane receptors, G protein coupled receptors, pathology, cancer

References

Abdulaev, N.G. 2003. Building a stage for interhelical play in rhodopsin. Trends Biochem. Sci. 28: 399–402.

Arora, P., Ricks, T.K., Trejo, J. 2007. Protease-activated receptor signalling, endocytic sorting and dysregulation in cancer. J. Cell Sci. 120: 921–928.

Balistreri, C.R., Caruso, C., Grimaldi, M.P., Listi, F., Vasto, S., Orlando, V., Campagna, A.M., Lio, D., Candore, G. 2007. CCR5 receptor: biologic and genetic implications in age-related diseases. Ann. N. Y. Acad. Sci. 1100: 162–172.

Barak, L.S., Oakley, R.H., Laporte, S.A., Caron, M.G. 2001. Constitutive arrestin-mediated desensitization of a human vasopressin receptor mutant associated with nephrogenic diabetes insipidus. Proc. Natl. Acad. Sci. U. S. A 98: 93–98.

Barzon, L., Pacenti, M., Masi, G., Stefani, A.L., Fincati, K., Palu, G. 2005. Loss of growth hormone secretagogue receptor 1a and overexpression of type 1b receptor transcripts in human adrenocortical tumors. Oncology 68: 414–421.

Biebermann, H., Krude, H., Elsner, A., Chubanov, V., Gudermann, T., Gruters, A. 2003. Autosomal-dominant mode of inheritance of a melanocortin-4 receptor mutation in a patient with severe early-onset obesity is due to a dominant-negative effect caused by receptor dimerization. Diabetes 52: 2984–2988.

Bourne, H.R., Sanders, D.A., Mccormick, F. 1991. The GTPase superfamily: conserved structure and molecular mechanism. Nature 349: 117–127.

Butler, A.A., Kesterson, R.A., Khong, K., Cullen, M.J., Pelleymounter, M.A., Dekoning, J., Baetscher, M., Cone, R.D. 2000. A unique metabolic syndrome causes obesity in the melanocortin-3 receptor-deficient mouse. Endocrinology 141: 3518–3521.

Cadet, P., Mantione, K.J., Stefano, G.B. 2003. Molecular identification and functional expression of mu 3, a novel alternatively spliced variant of the human mu opiate receptor gene. J. Immunol. 170: 5118–5123.

Chen, A.S., Marsh, D.J., Trumbauer, M.E., Frazier, E.G., Guan, X.M., Yu, H., Rosenblum, C.I., Vongs, A., Feng, Y., Cao, L., Metzger, J.M., Strack, A.M., Camacho, R.E., Mellin, T.N., Nunes, C.N., Min, W., Fisher, J., Gopal-Truter, S., Macintyre, D.E., Chen, H.Y., van der Ploeg, L.H. 2000. Inactivation of the mouse melanocortin-3 receptor results in increased fat mass and reduced lean body mass. Nat. Genet. 26: 97–102.

De Keyzer, Y., Rene, P., Beldjord, C., Lenne, F., Bertagna, X. 1998. Overexpression of vasopressin (V3) and corticotrophin-releasing hormone receptor genes in corticotroph tumours. Clin. Endocrinol. (Oxf) 49: 475–482.

Eaveri, R., Ben-Yehudah, A., Lorberboum-Galski, H. 2004. Surface antigens/receptors for targeted cancer treatment: the GnRH receptor/binding site for targeted adenocarcinoma therapy. Curr. Cancer Drug Targets. 4: 673–687.

Filardo, E.J., Graeber, C.T., Quinn, J.A., Resnick, M.B., Giri, D., Delellis, R.A., Steinhoff, M.M., Sabo, E. 2006. Distribution of GPR30, a seven membrane-spanning estrogen receptor, in primary breast cancer and its association with clinicopathologic determinants of tumor progression. Clin. Cancer Res. 12: 6359–6366.

Fuessel, S., Weigle, B., Schmidt, U., Baretton, G., Koch, R., Bachmann, M., Rieber, E.P., Wirth, M. P., Meye, A. 2006. Transcript quantification of Dresden G protein-coupled receptor (D-GPCR) in primary prostate cancer tissue pairs. Cancer Lett. 236: 95–104.

Gao, Y., Kitagawa, K., Hiramatsu, Y., Kikuchi, H., Isobe, T., Shimada, M., Uchida, C., Hattori, T., Oda, T., Nakayama, K., Nakayama, K. I., Tanaka, T., Konno, H., Kitagawa, M. 2006. Up-regulation of GPR48 induced by down-regulation of p27Kip1 enhances carcinoma cell invasiveness and metastasis. Cancer Res. 66: 11623–11631.

Govaerts, C., Srinivasan, S., Shapiro, A., Zhang, S., Picard, F., Clement, K., Lubrano-Berthelier, C., Vaisse, C. 2005. Obesity-associated mutations in the melanocortin 4 receptor provide novel insights into its function. Peptides 26: 909–1919.

Granovsky-Grisaru, S., Zaidoun, S., Grisaru, D., Yekel, Y., Prus, D., Beller, U., Bar-Shavit, R. 2006. The pattern of Protease Activated Receptor 1 (PAR1) expression in endometrial carcinoma. Gynecol. Oncol. 103: 802–806.

Gugger, M., White, R., Song, S., Waser, B., Cescato, R., Riviere, P., Reubi, J.C. 2008. GPR87 is an overexpressed G-protein coupled receptor in squamous cell carcinoma of the lung. Dis. Markers 24: 41–50.

Hata, K., Dhar, D.K., Watanabe, Y., Nakai, H., Hoshiai, H. 2007. Expression of metastin and a G-protein-coupled receptor (AXOR12) in epithelial ovarian cancer. Eur. J. Cancer 43 (9): 1452–1459.

Hirasawa, A., Shibata, K., Horie, K., Takei, Y., Obika, K., Tanaka, T., Muramoto, N., Takagaki, K., Yano, J., Tsujimoto, G. 1995. Cloning, functional expression and tissue distribution of human alpha 1c-adrenoceptor splice variants. FEBS Lett. 363: 56–260.

Hopkins, A.L., Groom, C.R. 2002. The druggable genome. Nat. Rev. Drug Discov. 1: 727–730.

Huang, Y., Fan, J., Yang, J., Zhu, G.Z. 2007. Characterization of GPR56 protein and its suppressed expression in human pancreatic cancer cells. Mol. Cell Biochem. 308: 133–139.

Jorda M.A., Rayman, N., Tas, M., Verbakel, S.E., Battista, N., Van, L.K., Lowenberg, B., Maccarrone, M., Delwel, R. 2004. The peripheral cannabinoid receptor Cb2, frequently expressed on AML blasts, either induces a neutrophilic differentiation block or confers abnormal migration properties in a ligand-dependent manner. Blood 104: 526–534.

Kitayama, J., Shida, D., Sako, A., Ishikawa, M., Hama, K., Aoki, J., Arai, H., Nagawa, H. 2004. Over-expression of lysophosphatidic acid receptor-2 in human invasive ductal carcinoma. Breast Cancer Res. 6: R640–R646.

Korner, M., Hayes, G.M., Rehmann, R., Zimmermann, A., Friess, H., Miller, L.J., Reubi, J.C. 2005. Secretin receptors in normal and diseased human pancreas: marked reduction of receptor binding in ductal neoplasia. Am. J. Pathol. 167: 959–968.

Kuo, W.H., Chang, L.Y., Liu, D.L., Hwa, H.L., Lin, J.J., Lee, P.H., Chen, C.N., Lien, H.C., Yuan, R.H., Shun, C.T., Chang, K.J., Hsieh, F.J. 2007. The interactions between GPR30 and the major biomarkers in infiltrating ductal carcinoma of the breast in an Asian population. Taiwan. J. Obstet. Gynecol. 46: 135–145.

Lagerstrom, M.C., Schioth, H.B. 2008. Structural diversity of G protein-coupled receptors and significance for drug discovery. Nat. Rev. Drug Discov. 7: 339–357.

Lee, Y.S., Poh, L.K., Loke, K.Y. 2002. A novel melanocortin 3 receptor gene (MC3R) mutation associated with severe obesity. J. Clin. Endocrinol. Metab 87 (3): 1423–1426.

Li, S., Huang, S., Peng, S.B. 2005. Overexpression of G protein-coupled receptors in cancer cells: involvement in tumor progression. Int. J. Oncol. 27: 1329–1339.

Lin-Su, K., Wajnrajch, M.P. 2002. Growth Hormone Releasing Hormone (GHRH) and the GHRH Receptor. Rev. Endocr. Metab Disord. 3: 313–323.

Magnusson, C., Ehrnstrom, R., Olsen, J., Sjolander, A. 2007. An increased expression of cysteinyl leukotriene 2 receptor in colorectal adenocarcinomas correlates with high differentiation. Cancer Res. 67: 9190–9198.

Mayo, K.E., Hammer, R.E., Swanson, L.W., Brinster, R.L., Rosenfeld, M.G., Evans, R.M. 1988. Dramatic pituitary hyperplasia in transgenic mice expressing a human growth hormone-releasing factor gene. Mol. Endocrinol. 2: 606–612.

Mazzuco, T.L., Chabre, O., Feige, J.J., Thomas, M. 2007. Aberrant GPCR expression is a sufficient genetic event to trigger adrenocortical tumorigenesis. Mol. Cell Endocrinol. 265–266: 23–28.

Mcclanahan, T., Koseoglu, S., Smith, K., Grein, J., Gustafson, E., Black, S., Kirschmeier, P., Samatar, A.A. 2006. Identification of overexpression of orphan G protein-coupled receptor GPR49 in human colon and ovarian primary tumors. Cancer Biol. Ther. 5: 419–426.

Merle, P., Kim, M., Herrmann, M., Gupte, A., Lefrancois, L., Califano, S., Trepo, C., Tanaka, S., Vitvitski, L., De La, Monte S., Wands, J.R. 2005. Oncogenic role of the frizzled-7/beta-catenin pathway in hepatocellular carcinoma. J. Hepatol. 43: 854–862.

Nelson, C.P., Challiss, R.A. 2007. "Phenotypic" pharmacology: the influence of cellular environment on G protein-coupled receptor antagonist and inverse agonist pharmacology. Biochem Pharmacol. 73: 737–751.

Nicolle, G., Comperat, E., Nicolaiew, N., Cancel-Tassin, G., Cussenot, O. 2007. Metastin (KISS-1) and metastin-coupled receptor (GPR54) expression in transitional cell carcinoma of the bladder. Ann. Oncol. 18: 605–607.

Parmigiani, R.B., Magalhaes, G.S., Galante, P.A., Manzini, C.V., Camargo, A.A., Malnic, B. 2004. A novel human G protein-coupled receptor is over-expressed in prostate cancer. Genet. Mol. Res. 3: 521–531.

Pierce, K.L., Luttrell, L.M., Lefkowitz, R.J. 2001. New mechanisms in heptahelical receptor signaling to mitogen activated protein kinase cascades. Oncogene 20: 1532–1539.

Pierce, K.L., Premont, R.T., Lefkowitz, R.J. 2002. Seven-transmembrane receptors. Nat. Rev. Mol. Cell Biol. 3: 639–650.

Rached, M., Buronfosse, A., Begeot, M., Penhoat, A. 2004. Inactivation and intracellular retention of the human I183N mutated melanocortin 3 receptor associated with obesity. Biochim. Biophys. Acta 1689: 229–234.

Ringel, M.D., Hardy, E., Bernet, V.J., Burch, H.B., Schuppert, F., Burman, K.D., Saji, M. 2002. Metastin receptor is overexpressed in papillary thyroid cancer and activates MAP kinase in thyroid cancer cells. J. Clin. Endocrinol. Metab 87: 2399.

Sanchez-Laorden, B.L., Jimenez-Cervantes, C., Garcia-Borron, J.C. 2007. Regulation of human melanocortin 1 receptor signaling and trafficking by Thr-308 and Ser-316 and its alteration in variant alleles associated with red hair and skin cancer. J. Biol. Chem. 282: 3241–3251.

Schlyer, S., Horuk, R. 2006. I want a new drug: G-protein-coupled receptors in drug development. Drug Discov. Today 11: 481–493.

Schoneberg, T., Schulz, A., Biebermann, H., Hermsdorf, T., Rompler, H., Sangkuhl, K. 2004. Mutant G-protein-coupled receptors as a cause of human diseases. Pharmacol. Ther. 104: 173–206.

Shashidhar, S., Lorente, G., Nagavarapu, U., Nelson, A., Kuo, J., Cummins, J., Nikolich, K., Urfer, R., Foehr, E.D. 2005. GPR56 is a GPCR that is overexpressed in gliomas and functions in tumor cell adhesion. Oncogene 24: 1673–1682.

Sodhi, A., Montaner, S., Gutkind, J.S. 2004. Does dysregulated expression of a deregulated viral GPCR trigger Kaposi's sarcomagenesis? FASEB J. 18: 422–427.

Spiegel, A.M. 1997. Inborn errors of signal transduction: mutations in G proteins and G protein-coupled receptors as a cause of disease. J. Inherit. Metab Dis. 20: 113–121.

Spiegel, A.M. 2000. G protein defects in signal transduction. Horm. Res. 53: 17–22.

Spiegel, A.M., Weinstein, L.S. 2004. Inherited diseases involving g proteins and g protein-coupled receptors. Annu. Rev. Med. 55: 27–39.

Stojanovic, A., Hwa, J. 2002. Rhodopsin and retinitis pigmentosa: shedding light on structure and function. Receptors. Channels 8: 33–50.

Tao, Y.X. 2005. Molecular mechanisms of the neural melanocortin receptor dysfunction in severe early onset obesity. Mol. Cell Endocrinol. 239: 1–14.

Tao, Y.X. 2006. Inactivating mutations of G protein-coupled receptors and diseases: structure-function insights and therapeutic implications. Pharmacol. Ther. 111: 949–973.

Tao, Y.X., Segaloff, D.L. 2004. Functional characterization of melanocortin-3 receptor variants identify a loss-of-function mutation involving an amino acid critical for G protein-coupled receptor activation. J. Clin. Endocrinol. Metab 89: 3936–3942.

Vischer, H.F., Leurs, R., Smit, M.J. 2006. HCMV-encoded G-protein-coupled receptors as constitutively active modulators of cellular signaling networks. Trends Pharmacol. Sci. 27: 56–63.

Wilson, S., Bergsma, D.J., Chambers, J.K., Muir, A.I., Fantom, K.G., Ellis, C., Murdock, P.R., Herrity, N.C., Stadel, J.M. 1998. Orphan G-protein-coupled receptors: the next generation of drug targets? Br. J. Pharmacol. 125: 1387–1392.

Yang, M., Zhong, W.W., Srivastava, N., Slavin, A., Yang, J., Hoey, T., An, S. 2005. G protein-coupled lysophosphatidic acid receptors stimulate proliferation of colon cancer cells through the {beta}-catenin pathway. Proc. Natl. Acad. Sci. U. S. A 102: 6027–6032.

First Page

33

Last Page

47

Language

eng

Share

COinS